Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …

Background Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with
activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or …

The number of cancer survivors continues to increase in the United States because of the
growth and aging of the population as well as advances in early detection and treatment. To …

PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …

Background Venetoclax plus obinutuzumab has been established as a fixed-duration
treatment regimen for patients with chronic lymphocytic leukaemia. We compared the long …

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily
Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant …

Herein, we present the long-term follow-up of the randomized E1912 trial comparing the
long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and …

Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …